SCHEDULE 13G: Nongae Apple Association 1st Discloses 5.7% Passive Stake in Liminatus Pharma, Inc.

Nongae Apple Association 1st has reported a 5.7% passive ownership stake in Liminatus Pharma, Inc. following the consummation of a business combination.

Summary

• Nongae Apple Association 1st, based in the Republic of Korea, has filed a Schedule 13G indicating beneficial ownership of Liminatus Pharma, Inc. common stock.
• The reporting person beneficially owns 1,470,000 shares of Liminatus Pharma, Inc. common stock.
• This ownership represents 5.7% of the outstanding common stock, calculated based on 26,014,633 shares outstanding upon the consummation of the Business Combination on April 30, 2025.
• Nongae Apple Association 1st holds sole voting power and sole dispositive power over all 1,470,000 shares.
• The shares were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Liminatus Pharma, Inc.

Sentiment

Score: 6

Explanation: The disclosure of a new significant passive shareholder is generally a neutral to slightly positive event, indicating investor interest without signaling immediate strategic shifts or financial performance changes.

Positives

• Disclosure of a new significant shareholder, Nongae Apple Association 1st, holding a 5.7% stake, which can be viewed as a vote of confidence in Liminatus Pharma, Inc.

Risks

• The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, mitigating immediate control-related risks.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Liminatus Pharma, Inc.'s future performance or strategic direction.

Management Comments

• Hunjoo (Mary) Song, as the Authorized Representative for Nongae Apple Association 1st, certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing is a standard disclosure of beneficial ownership and does not provide specific insights into broader industry trends or competitive landscape beyond the fact of a new significant investor in the pharmaceutical sector.

Stakeholder Impact

• Shareholders: The disclosure informs existing and potential shareholders of a new significant passive investor, Nongae Apple Association 1st, holding 5.7% of the common stock.

Key Dates

Keywords

Liminatus Pharma, Nongae Apple Association, Schedule 13G, beneficial ownership, common stock, passive investment, SEC filing, equity stake